Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8305984 | 0.89 | RAB9A (0.53) | RAB9APKMNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1470779 | 0.88 | RAB9A (0.47) | RAB9APKMNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1471433 | 0.88 | HPGD (0.47) | RAB9APKMNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14382950 | 0.88 | HPGD (0.49) | RAB9APKMNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1471258 | 0.88 | RAB9A (0.47) | RAB9APKMNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1470886 | 0.86 | RAB9A (0.45) | RAB9APKMNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1471240 | 0.85 | RAB9A (0.47) | RAB9APKMNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1471333 | 0.85 | RAB9A (0.49) | RAB9APKMNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1471308 | 0.85 | HPGD (0.53) | RAB9APKMNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1473205 | 0.85 | RAB9A (0.53) | RAB9APKMNPC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276610-B2 | Aryl piperidine amides | JANSSEN PHARACEUTICA, NV (BE) | 2007-10-02 | — | — | US | claimed |
| JP-2007503440-A | — | — | 2007-02-22 | — | — | JP | claimed |
| EP-1660472-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| WO-2005021525-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-10 | — | — | WO | claimed |
| US-20050049239-A1 | Aryl piperidine amides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | claimed |
| US-7915420-B2 | Aryl piperidine amides | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7915420-B2 | Aryl piperidine amides | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7915420-B2 | Aryl piperidine amides | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20080009521-A1 | Aryl Piperidine Amides | HUANG CHARLES Q | 2008-01-10 | — | — | US | disclosed |
| US-20080009521-A1 | Aryl Piperidine Amides | HUANG CHARLES Q | 2008-01-10 | — | — | US | disclosed |
| US-20080009521-A1 | Aryl Piperidine Amides | HUANG CHARLES Q | 2008-01-10 | — | — | US | disclosed |
| US-7276610-B2 | Aryl piperidine amides | JANSSEN PHARACEUTICA, NV (BE) | 2007-10-02 | — | — | US | disclosed |
| US-7276610-B2 | Aryl piperidine amides | JANSSEN PHARACEUTICA, NV (BE) | 2007-10-02 | — | — | US | disclosed |
| US-7276610-B2 | Aryl piperidine amides | JANSSEN PHARACEUTICA, NV (BE) | 2007-10-02 | — | — | US | disclosed |
| EP-1660472-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021525-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021525-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-10 | — | — | WO | disclosed |
| US-20050049239-A1 | Aryl piperidine amides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009521-A1 | Aryl Piperidine Amides | BDNF, NTRK2, OPRL1 | RAB9A 3100/4885PKM 1881/4885NPC1 514/4885 |
| US-20050049239-A1 | Aryl piperidine amides | BDNF, NTRK2, OPRL1 | RAB9A 3100/4885PKM 1881/4885NPC1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.